New hope for tough lymphoma: targeted drug combo shows promise in early trial
NCT ID NCT04665765
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treatment. The study aims to see how many patients achieve a complete response after two cycles and to monitor for unacceptable toxicities. About 41 participants are being enrolled at City of Hope Medical Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (PolaR-ICE)
- What this could lead to
- If successful, this combination could offer a more effective salvage therapy for patients whose lymphoma has returned or not responded to initial treatment, potentially improving remission rates before a stem cell transplant.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 41 participants, so results may not apply broadly. The treatment combines multiple strong drugs, which can cause serious side effects like infections, nerve damage, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA UNCLASSIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- New combo therapy aims to stop aggressive lymphoma relapse
- New combo approach aims to boost CAR-T success in tough lymphoma
- New combo attack on lymphoma shows promise in early trial